A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.

The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.

The conference’s abstract drop features ASC4First in its plenary session.

Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.

An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.